Eisai’s IQLIK Approval and the Race to Make Alzheimer's a Curable Disease

Strong Q1 growth from Lenvima, Dayvigo and Leqembi; subcutaneous IQLIK launch promises to expand patient access and shift the competitive landscape.

4523.T · Earnings Call · 2026-08-03

Eisai's fiscal first quarter delivered a double-digit top- and bottom-line beat, and management used the results call to frame an ambitious long-term vision: transforming Alzheimer's disease from a progressive, fatal condition into a curable one. The company's three growth products — Lenvima, Dayvigo and Leqembi — again powered results, but the real news was the FDA approval of IQLIK initiation treatment, a subcutaneous auto-injector that could unlock home administration and expand the addressable patient base.

The 3L Engine Delivers

Revenue for the quarter rose 15.6% year-on-year to ¥234.3 billion, with operating profit up 19.2% to ¥24.7 billion. CFO Takuya Oyama attributed the growth to the company's “3L” portfolio and noted that the major products – Lenvima, Dayvigo and Leqembi – all contributed.

“Revenue for the first quarter of fiscal year 2026 was JPY 234.3 billion, a 15.6% increase from a year earlier.” — Takuya Oyama, CFO · 2026-08-03

Management also flagged that the company posted its first-ever profit on a commercial basis (excluding Leqembi's R&D), a milestone that speaks to the improving unit economics as Leqembi scales. The cost-of-sales ratio fell across all three key products, driven by manufacturing efficiencies and favorable mix.

IQLIK: A New Treatment Paradigm

On July 13, 2026, the FDA approved Leqembi IQLIK for initiation treatment, paving the way for subcutaneous dosing with an auto-injector. The formulation’s value proposition extends well beyond convenience — it enables home administration after two supervised doses, reducing the burden on patients, care partners, and healthcare infrastructure. COO Haruo Naito described the vision succinctly:

The major value of IQLIK comes not only from its new formulation, but after two consecutive treatments under the direct guidance of health care professionals, home administration becomes possible for patients when deemed appropriate.
Haruo Naito, COO · 2026-08-03

Management expects the launch to begin in late August, with prescriptions already starting at some institutions. The company is simultaneously building out the supporting infrastructure: treatment continuation is aided by blood-based biomarkers (BBM) for diagnosis, and the combination of BBM with IQLIK is expected to streamline the entire care pathway from diagnosis to long-term treatment.

Turning the Competitive Tide

A key competitive dynamic is the conversion of patients from Eli Lilly's Kisunla, which is typically given for a fixed duration. In the Q&A, Katsuya Haruna, Head of Global Leqembi Business, confirmed that conversion is already happening:

“patients who stopped the treatment of Kisunla, it is possible to transition or convert to LEQEMBI. And in actual clinical practice, we are seeing such conversions.” — Katsuya Haruna, Head of Global LEQEMBI Business · 2026-08-03

This is not a hypothetical — the real-world evidence from the LEADER study, presented at AAIC 2026, shows that 82.5% of patients were cognitively stable or improved and that 78.9% of those who have been on therapy for over 18 months have chosen to continue with maintenance treatment. The company is positioning IQLIK as a way to keep patients on therapy longer, countering the fixed-duration mindset that could limit the market.

Pipeline: Beyond Amyloid

While Leqembi remains the immediate growth driver, management outlined a broader drug discovery platform aimed at tackling the full Alzheimer's pathology. The anti-MTBR tau antibody etalanetug showed promising biomarker data (62% reduction in CSF eMTBR-tau243 at 3 months), and the orexin agonist ledasorexton is moving through Phase II. Naito described the long-term ambition:

“We call such long-term vision of combining pre-onset intervention and suppression of disease progression, make AD curable.” — Haruo Naito, COO · 2026-08-03

This pivot toward Tau Pathology and neurodegeneration represents a strategic bet beyond amyloid, potentially differentiating Eisai as the disease-modifying landscape matures.

Recurring Themes and Risks

Investors should monitor the same risks that have dominated prior calls: reimbursement timing for IQLIK under Medicare, the rollout of commercial insurance coverage in China, and the impact of foreign exchange. In the prior quarter call from February 2026, Haruna had already signaled that the medical exception process was yielding high reimbursement rates—over 80%—and that better coverage would come from January 2027:

“Currently, in more than 80% of the cases, insurance is reimbursed. In January 2027, after listing in the formulary, smoother reimbursement is expected.” — Katsuya Haruna, Head of US LEQEMBI Business · 2026-02-09

But the company's confidence in IQLIK is built on more than reimbursement. As Haruna noted then:

“After 18 months administration and then about 80% or over 80% of patients who have completed 18 months treatment wish to switch to the maintenance treatment.” — Katsuya Haruna, Head of US LEQEMBI Business · 2026-02-09

These recurring endorsements from physicians and patients are evidence that the convenience of IQLIK is not just a nice-to-have but a fundamental driver of adherence and market share.

Eisai enters fiscal 2026 with a growth algorithm that is rare in pharma: three major products gaining share, a new formulation just approved, and a pipeline that could extend the franchise well beyond the current decade. The key question is whether the company can translate regulatory wins into durable commercial execution. So far, the first quarter suggests it is on track.